Essais liés12clinical trials
VilleAdelaidelocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06798896

Ouvrir le site du centre

Essais cliniques associés

12
MoléculeIndication / populationPhaseNCTTitreStatut
JNJ-63733657 Alzheimer Phase 2 NCT04619420 Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease TERMINATED
Survodutide Maladie rénale chronique Phase 3 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) COMPLETED
Pulsed Field Ablation Maladie coronarienne Non applicable NCT06106594 VOLT CE Mark Study ACTIVE_NOT_RECRUITING
Dapagliflozin 10 mg/day (oral) Maladie rénale chronique Phase 3 NCT05374291 The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD ACTIVE_NOT_RECRUITING
BB-031 Accident vasculaire cérébral Phase 2 NCT06226805 Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) RECRUITING
Tenecteplase Accident vasculaire cérébral Phase 3 NCT07361302 TENACITY — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well RECRUITING
Vicadrostat Insuffisance cardiaque Phase 3 NCT06424288 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure RECRUITING
WiSE System Insuffisance cardiaque Non applicable NCT02922036 SOLVE-CRT — Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients ACTIVE_NOT_RECRUITING
Xolatryp Maladie coronarienne Phase 2 NCT07362446 PROTECT-MI — Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction RECRUITING
SPN-817 Épilepsie Phase 2 NCT06798896 RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures RECRUITING
SC291 SEP Phase 1 NCT05878184 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) ACTIVE_NOT_RECRUITING
Obinutuzumab Cancer Phase 3 NCT06084936 GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma RECRUITING